62 Participants Needed

Stereotactic Radiosurgery for Brain Metastases from Lung Cancer

Recruiting at 7 trial locations
LP
BI
Overseen ByBrandon Imber, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 6 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Stereotactic Radiosurgery for brain metastases from lung cancer?

Research shows that Stereotactic Radiosurgery (SRS) is effective in prolonging survival for patients with a single brain metastasis and maintaining functional independence for those with up to three brain metastases. It is a precise treatment option that has become standard for patients with few metastatic brain lesions, offering an alternative to whole brain radiation therapy.12345

Is stereotactic radiosurgery (SRS) safe for humans?

Stereotactic radiosurgery (SRS), including treatments like CyberKnife and Gamma Knife, has been shown to be generally safe for treating brain metastases and lung tumors, with studies reporting acceptable levels of side effects and good local tumor control.678910

How does the treatment Stereotactic Radiosurgery (SRS) for brain metastases from lung cancer differ from other treatments?

Stereotactic Radiosurgery (SRS) is unique because it delivers a highly focused, single session of radiation directly to the brain metastases, minimizing exposure to surrounding healthy tissue. This approach reduces the need for invasive surgery and avoids the broader side effects associated with whole brain radiation therapy.12111213

Research Team

LP

Luke Pike, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults with small cell lung cancer that has spread to the brain. They must be able to consent, have a good performance status (able to carry out daily activities), and women must not be pregnant. People can't join if they've had previous brain radiotherapy, are pregnant or breastfeeding, can't undergo MRI scans, or have uncontrolled systemic disease.

Inclusion Criteria

The patient or legally authorized representative is able to provide informed consent
I am not able to become pregnant or I have a negative pregnancy test.
I have up to 10 brain tumors identified by MRI.
See 3 more

Exclusion Criteria

You cannot have an MRI with a special dye to show clearer pictures of your brain or spine.
Pregnant or lactating women
I have a severe illness with no treatment options, confirmed by scans within the last 3 months.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive stereotactic radiosurgery (SRS) for brain metastases from small cell lung cancer

6 weeks

Follow-up

Participants are monitored for overall survival and effectiveness of the treatment

6 months

Treatment Details

Interventions

  • Stereotactic Radiosurgery
Trial OverviewThe study is testing Stereotactic Radiosurgery (SRS) as a treatment for patients with newly diagnosed brain metastases from small cell lung cancer. It will involve precise delivery of radiation to the brain tumors without affecting surrounding healthy tissue.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Participants with small cell lung cancer with brain metastasesExperimental Treatment2 Interventions
Participants may be newly diagnosed small cell lung cancer with brain metastases at initial staging, or can alternatively be patients who develop brain metastases on therapy or during surveillance of systemic disease.

Stereotactic Radiosurgery is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:

🇪🇺
Approved in European Union as Stereotactic Radiosurgery for:
  • Brain tumors
  • Metastatic brain tumors
  • Arteriovenous malformations (AVMs)
  • Trigeminal neuralgia
  • Acoustic neuromas
🇺🇸
Approved in United States as Stereotactic Radiosurgery for:
  • Brain tumors
  • Metastatic brain tumors
  • Arteriovenous malformations (AVMs)
  • Trigeminal neuralgia
  • Acoustic neuromas
  • Liver tumors
  • Lung tumors
  • Spinal cord tumors
🇨🇦
Approved in Canada as Stereotactic Radiosurgery for:
  • Brain tumors
  • Metastatic brain tumors
  • Arteriovenous malformations (AVMs)
  • Trigeminal neuralgia
  • Acoustic neuromas
🇯🇵
Approved in Japan as Stereotactic Radiosurgery for:
  • Brain tumors
  • Metastatic brain tumors
  • Arteriovenous malformations (AVMs)
  • Trigeminal neuralgia
  • Acoustic neuromas
🇨🇳
Approved in China as Stereotactic Radiosurgery for:
  • Brain tumors
  • Metastatic brain tumors
  • Arteriovenous malformations (AVMs)
  • Trigeminal neuralgia
  • Acoustic neuromas
🇨🇭
Approved in Switzerland as Stereotactic Radiosurgery for:
  • Brain tumors
  • Metastatic brain tumors
  • Arteriovenous malformations (AVMs)
  • Trigeminal neuralgia
  • Acoustic neuromas

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

Findings from Research

Stereotactic radiosurgery (SRS) using CyberKnife for large brain metastasis cavities (≥2 cm) showed a local failure rate of 24%, indicating it can effectively control local disease after surgery.
Patients with synchronous metastases had a higher risk of distant brain failure, suggesting that while SRS can delay the need for whole brain radiation therapy (WBRT), careful monitoring is needed for those with multiple metastases.
Intracranial control after Cyberknife radiosurgery to the resection bed for large brain metastases.Vogel, J., Ojerholm, E., Hollander, A., et al.[2018]
Stereotactic radiosurgery (SRS) can effectively control brain metastases from small cell lung cancer (SCLC) for lesions smaller than 2 cm, with local control rates of 81% at 6 months and 69% at 12 months.
However, larger lesions (>2 cm) are more likely to fail treatment, especially if treated with doses less than 16 Gy, highlighting the importance of aggressive treatment for patients with limited CNS involvement and controlled systemic disease.
Local recurrence and survival following stereotactic radiosurgery for brain metastases from small cell lung cancer.Rava, P., Sioshansi, S., DiPetrillo, T., et al.[2016]
In a study of 156 non-small cell lung cancer patients with 1-4 brain metastases, stereotactic radiosurgery (LINAC-SRS) did not show significantly better overall survival compared to whole-brain radiotherapy (WBRT) or WBRT plus radiotherapy boost (WBRT+RTB).
The median overall survival was not reached for the LINAC-SRS group, while it was 33.3 months for WBRT and 27.9 months for WBRT+RTB, indicating that LINAC-SRS may not provide a clear advantage in treatment outcomes for these patients.
Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.Chen, Z., Zhou, L., Zhao, M., et al.[2022]

References

Intracranial control after Cyberknife radiosurgery to the resection bed for large brain metastases. [2018]
Local recurrence and survival following stereotactic radiosurgery for brain metastases from small cell lung cancer. [2016]
Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases. [2022]
Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. [2016]
New developments in intracranial stereotactic radiotherapy for metastases. [2022]
Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis. [2022]
Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer. [2022]
Predictors of linear accelerator versus Gamma Knife stereotactic radiosurgery use for brain metastases in the United States. [2022]
CyberKnife stereotactic ablative radiotherapy for lung tumors. [2022]
Efficacy and safety of CyberKnife radiosurgery in elderly patients with brain metastases: a retrospective clinical evaluation. [2021]
11.United Statespubmed.ncbi.nlm.nih.gov
Role of Gamma Knife Radiosurgery in Small Cell Lung Cancer: A Multi-Institutional Retrospective Study of the International Radiosurgery Research Foundation (IRRF). [2021]
Medical and health economic assessment of radiosurgery for the treatment of brain metastasis. [2021]
13.United Statespubmed.ncbi.nlm.nih.gov
Radiosurgery for solitary brain metastases using the cobalt-60 gamma unit: methods and results in 24 patients. [2019]